Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

by admin | Jun 22, 2026 | Health

Spread the love

At 4 years, dostarlimab plus chemotherapy reduced the risk for death by two thirds among patients with dMMR/MSI-H advanced endometrial cancer, pointing to curative potential, experts say.
Medscape Medical News

← Why Gaza’s genocide death toll is deliberately undercounted Can a Constipation Drug Clear Depression’s ‘Brain Fog’? →

Written By

Written by Albert Pham, News Curator and Blogger

AI Startup Red Queen Bio Uses Artificial Intelligence to Prepare for a Future Pandemic

Sep 28, 2026 | albertpham, Economy_finances, Health, Technology

Red Queen Bio is using AI to design antibody drugs against novel pathogens, highlighting the growing role of artificial intelligence in pandemic preparedness and biotech.

Harvard, MIT Professors Move to Canada Amid U.S. Research Funding Cuts

Sep 25, 2026 | albertpham, Economy_finances, Health, Politics

Harvard and MIT professors are moving to Canadian universities as Canada invests billions to attract global researchers amid U.S. research funding uncertainty.

Americans Could Lose Access to Cheaper Canadian Prescription Drugs

Sep 22, 2026 | albertpham, Economy_finances, Health

U.S. customs changes could restrict Americans’ access to cheaper prescription drugs from Canada and other foreign pharmacies starting in October.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

Written By

Related Posts

AI Startup Red Queen Bio Uses Artificial Intelligence to Prepare for a Future Pandemic

Harvard, MIT Professors Move to Canada Amid U.S. Research Funding Cuts

Americans Could Lose Access to Cheaper Canadian Prescription Drugs

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated